

Resilience to dominant genetic disease in the healthy elderly

Paul Lacaze^{1*}, Robert Sebra^{2,3*}, Moeen Riaz¹, Jane Tiller¹, Jerico Revote¹, James Phung¹, Emily J Parker¹, Suzanne G Orchard¹, Jessica E Lockery¹, Rory Wolfe¹, Maya Strahl², Ying C Wang², Rong Chen^{2,3}, Daniel Sisco³, Todd Arnold³, Bryony A Thompson⁴, Daniel D Buchanan^{4,5}, Finlay A Macrae⁴, Paul A James⁴, Walter P Abhayaratna⁶, Trevor J Lockett⁷, Peter Gibbs⁸, Andrew M Tonkin¹, Mark R Nelson^{1,9}, Christopher M Reid^{1,10}, Robyn L Woods¹, Anne M Murray¹¹, Ingrid Winship^{4#}, John J McNeil^{1#} & Eric Schadt^{2,3#}

*Joint first authors, # Joint senior authors

¹*Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.*

²*Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, USA.*

³*Sema4, Stamford, CT, USA*

⁴*Department of Genomic Medicine; Family Cancer Clinic, Department of Medicine, Department of Pathology, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.*

⁵*Colorectal Oncogenomics Group, Department of Clinical Pathology, University of Melbourne, VIC, Australia*

⁶*College of Health and Medicine, the Australian National University, Canberra, Australia.*

⁷*CSIRO Health and Biosecurity, North Ryde, Australia*

⁸*The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.*

⁹*Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia*

¹⁰*School of Public Health, Curtin University, Perth, WA, Australia*

¹¹*Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, MN, USA*

*Corresponding author: paul.lacaze@monash.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 ABSTRACT

2 Here we describe genomic screening of the healthy elderly to identify those resilient to adult-onset genetic
3 disease, despite being at exceptionally high genetic risk. We sequenced 13,131 individuals aged 70 or
4 older (mean age 75 years) from the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
5 Participants had no prior history of cardiovascular disease, life-threatening cancer, persistent physical
6 disability or dementia. We compared the prevalence of pathogenic variants in medically actionable
7 autosomal dominant disease genes with that from the UK Biobank population, and assessed their clinical
8 impact using personal medical history and adjudicated study outcomes during 4.5 years of follow-up. The
9 frequency of pathogenic variants was less than reported among the younger UK Biobank population,
10 suggesting these variants confer a survival disadvantage during the middle years of life. Yet we identified
11 141 individuals with pathogenic variants free of any associated disease up to average age 79.5 years.
12 Further study of these elderly resilient individuals might help uncover genetic mechanisms that protect
13 against the development of disease.

14 INTRODUCTION

15 Few genetic studies focus on the healthy elderly (1-6). By contrast, most genetic studies ascertain
16 participants based on clinical presentation and/or family history of genetic disease (7-11). The healthy
17 elderly, especially those who remain unaffected despite carrying genetic risk factors, are uniquely valuable.
18 These resilient individuals may be enriched for protective genetic factors, which if understood, could inform
19 the design of novel preventive or therapeutic strategies (12).

20 Previously, we identified rare exceptional ‘resilience candidates’ with protection against severe Mendelian
21 childhood disorders by analysis of 589,306 genomes (13). Here, we take a new approach to identify
22 individuals resilient to adult-onset genetic disease by direct screening of a healthy elderly cohort (14). As
23 a means of identifying factors that protect against disease in resilient individuals, screening the healthy
24 elderly provides a path to employ statistical approaches for their identification (15). The number of
25 individuals in healthy elderly populations resilient to adult-onset disease is significantly higher than those
26 resilient to childhood-onset disorders, where extremely large numbers need to be screened to identify small
27 numbers of resilient individuals (13).

28 To estimate the rate at which individuals from a healthy elderly population are resilient to adult-onset,
29 autosomal dominant disease, despite carrying pathogenic variants for a lifetime, we sought to screen 13,131
30 healthy elderly individuals enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial (16-
31 18). We focused on screening for pathogenic variants in dominant genes of high clinical interest, defined
32 as medically actionable by the American College of Medical Genetics and Genomics (ACMG) (19).
33 Sequencing of participants aged minimum 70 years (mean age 75 years) is accompanied by documented
34 outcome assessment from a clinical trial, to confirm the presence or absence of associated disease.

35 METHODS

36 STUDY POPULATION

37 All participants were enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) study, a
38 randomized, placebo-controlled trial for daily low-dose aspirin (16-18). Study design (20), recruitment
39 (21), baseline characteristics (22) and results (16-18) have been published previously. Genetic analysis
40 was conducted on 13,131 samples from Australian participants aged 70 years or older at enrolment, free
41 from cardiovascular disease, dementia diagnosis, physical disability, or serious illness likely to cause
42 death within 5 years (ASPREE eligibility criteria in Supplementary Appendix).

43 DNA SEQUENCING AND VARIANT ANALYSIS

44 A custom panel of genes with Mendelian inheritance and disease-association was designed, including 55
45 dominant genes defined as medically actionable by the American College of Medical Genetics and
46 Genomics (ACMG) (19). Following standard protocols, DNA was extracted and sequenced using the
47 Thermo Fisher Scientific S5TM XL system, to average 200X depth (see Supplementary Appendix).
48 Variants with ‘pathogenic’ or ‘likely pathogenic’ annotation (23) and/or high-confidence predicted loss-
49 of-function in coding regions (24) were curated following ACMG/AMP Standards and Guidelines for the
50 Interpretation of Sequence Variants (25), including review by laboratory scientists and a clinical geneticist.
51 Analysis was restricted to single nucleotide variants and small insertions/deletions. Variants of uncertain
52 significance or conflicting interpretations of pathogenicity were excluded.

53 PHENOTYPES AND CLINICAL OUTCOME ASSESSMENT

54 Available disease outcomes from the ASPREE study associated with autosomal dominant genetic
55 conditions are summarized in Table S1. This includes self-reported medical history at enrolment (cancer
56 history by type) and study endpoints collected during mean 4.5 years follow-up (to mean age 79.5 years).
57 Adjudicated secondary endpoints included cancers (by type), cardiovascular events (stroke, coronary
58 heart disease, myocardial infarction, hospitalisation for heart failure) and all-cause mortality. Coding and
59 adjudication of endpoints has been described previously (16-18).

60 DISEASE ASSOCIATION AND IDENTIFICATION OF RESILIENT CASES

61 We compared the prevalence of pathogenic variants in autosomal dominant genes in ASPREE versus the
62 UK Biobank, a younger population of 49,960 adults aged average 58 years recruited from the UK general
63 population (26). We grouped dominant genes together into related groups, then calculated the relative risk
64 of associated disease per group in ASPREE variant carriers and 12,936 non-carriers in the trial, using
65 personal medical history and prospective diagnoses during follow-up. We identified all pathogenic variant
66 carriers with no evidence of associated disease symptoms to mean age 79.5 years (resilience cases).

67 RESULTS

68 PARTICIPANTS

69 The characteristics of the 13,131 sequenced participants are shown in Table 1. The mean age at enrolment
70 was 75 years and most were White/Caucasian. Participants had no personal history of cardiovascular
71 events at entry to the trial (16, 22). Participants with personal cancer history were not excluded from
72 enrolment, other than those with cancer diagnoses deemed likely to cause death within five years (22).

73 **Table 1. Characteristics of Sequenced Participants at Enrolment**

	ASPREE N=13,131 (mean age 75 years)
Female sex – no. (%)	7056 (54)
Age in years – no. (%)	
70-74 yr	7,894 (60)
75-79 yr	3,406 (26)
≥80 yr	1,831 (14)
Race or ethnic group^a – no. (%)	
White/Caucasian	12,953 (99)
Other	178 (1)
Obese (BMI ≥ 30 kg/m²)^b (%)	28
Current smoking (%)	4
Heart, stroke or vascular disease^c (%)	0
Personal cancer history (%)	20
Breast cancer history (%)	4
Colorectal cancer history (%)	3

74

75 ^a Self-report.

76 ^b Obese was defined as body-mass index (weight in kilograms divided by the square of the height in meters) of ≥30.

77 ^c Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study (22)

78

79 PATHOGENIC VARIANTS IN MEDICALLY ACTIONABLE GENES

80 We detected 172 different pathogenic or likely pathogenic variants meeting ACMG/AMP guidelines (25)
81 in 59 genes. Of these, 129 variants were in dominant genes, detected in 176 participants. We validated a
82 representative sample of 10% of these 129 variants by Sanger sequencing (N=14), with 100% concordance.
83 The highest number of pathogenic variants found in any one dominant gene was N=22 (*BRCA2* and *KCNQ1*)

84 We compared the prevalence of pathogenic variants in selected autosomal dominant genes in ASPREE
85 versus the UK Biobank, a younger population of 49,960 adults aged average 58 years (26) (Table 2). We
86 did this to determine if the prevalence of medically actionable variants was depleted in the healthy elderly,
87 compared with a population-based cohort, irrespective of associated disease outcomes or age.

88 Table 2 shows the number of variants detected in both studies across selected gene groups, and the
89 prevalence of pathogenic variants per 1000 individuals (see Table S2 for individual gene frequencies). In
90 ASPREE, pathogenic variants in medically actionable dominant genes were found in 1 in 75 healthy elderly
91 adults (13 per 1000 participants). This was a lower carrier rate to 1 in 50 (20 per 1000) reported in the UK
92 Biobank (26). Some genes had similar frequencies of pathogenic variants between the two studies. Notable
93 differences were the lower prevalence of *BRCA2* variants observed in ASPREE, and lower prevalence of
94 female *BRCA1/2* carriers (2 per 1000) versus the UK Biobank (4 per 1000).

95 We found no individuals carrying two or more variants in any autosomal recessive gene (homozygotes or
96 compound heterozygotes). However, we found two individuals carrying pathogenic variants in two
97 different dominant genes (*PMS2+KCNQ1* and *MYBPC3+LDLR* respectively).

98 **Table 2. Pathogenic Variants in Selected Autosomal Dominant Medically Actionable Genes in**
 99 **ASPREE versus the UK Biobank.**

	UK Biobank ^a N=49,960		ASPREE N=13,131	
Average age – yrs (1st-3rd quartiles)	58 (45 to 71)		75 (72 to 77)	
Female sex – %	55		54	
Gene groups	No. of carriers	Carriers per 1000^b	No. of carriers	Carriers per 1000^b
ACMG59TM genes Autosomal dominant (N=55)	994	20	176	13
Hereditary breast and ovarian cancer				
<i>BRCA1</i>	60	1	11	1
<i>BRCA2</i>	166	3.5	22	1.5
<i>BRCA1&BRCA2 Females</i>	110	4	15	2
Lynch syndrome				
<i>PMS2</i>	59	1	12	1
<i>MSH6, MLH1, MSH2</i>	78	1.5	8	0.5
Familial hypercholesterolemia (pathogenic) <i>LDLR, APOB, PCSK9</i>	68	1.5	13	1
Romano-Ward long QT syndrome types 1,2, 3, Brugada				
<i>KCNQ1</i>	55	1	22	1.5
<i>KCNH2, SCN5A</i>	61	1	17	1.5
Hypertrophic cardiomyopathy, Dilated cardiomyopathy				
<i>MYBPC3</i>	50	1	15	1
<i>MYH7, MYH11, LMNA, MYL3, TNNT2, TNNI3, GLA, MYL2</i>	94	2	10	1
Arrhythmogenic right-ventricular cardiomyopathy				
<i>PKP2</i>	55	1	12	1
<i>DSC2, DSG2, DSP, TMEM43</i>	98	2	10	1
Hereditary paraganglioma-pheochromocytoma syndrome <i>SDHB, SDHC, SDHD</i>	33	0.5	5	0.5

100

101 ^aVan Hout et al, *Whole exome sequencing and characterization of coding variation in 49,960 individuals in the UK*
 102 *Biobank*, bioRxiv preprint first posted online Mar. 9, 2019

103 ^bCarrier rate per 1000 has been rounded to the nearest 0.5

104 CLINICAL IMPACT OF PATHOGENIC VARIANTS OVER THE LIFETIME OF PARTICIPANTS

105 We compared the relative risk of associated disease in ASPREE variant carriers versus 12,936 non-
106 carriers in the cohort, to mean age 79.5 years. In almost all cases, we found no statistically significant
107 difference in relative risk of associated disease between pathogenic variant carriers and non-carriers,
108 despite detection of pathogenic variants that infer high lifetime disease risk (Table S3). This was due to
109 the high proportion of ASPREE participants who were free of the disease expected to be associated with
110 the pathogenic variant at end of trial (Table S4).

111 The two exceptions were female *BRCAl/2* pathogenic variant carriers in ASPREE who were at increased
112 risk of breast cancer versus non-carrier females ($P=0.0003$) and carriers of pathogenic variants in inherited
113 cardiac disorder genes, who were at increased risk of rapid/sudden cardiac death versus non-carriers
114 ($P<0.0001$). In the latter group, absolute risk was still low. Among 91 variant carriers, only two sudden
115 cardiac deaths occurred in trial (97.8% associated disease-free). We compared the likelihood of death
116 from any cause between pathogenic variant carriers and non-carriers to mean age 79.5 years, and found
117 no statistically significant differences for any genes (Table S5).

118

119 IDENTIFICATION OF RESILIENT INDIVIDUALS

120 To identify resilient individuals in the ASPREE population for medically actionable autosomal dominant
121 genetic conditions, we excluded all pathogenic variant carriers in the cohort who had any symptoms of
122 associated disease to mean age 79.5 years (for conditions where direct clinical phenotypes were available).
123 This identified a total of 141 resilient candidates, who despite carrying pathogenic variants in dominant
124 medically actionable genes, showed no apparent associated disease symptoms to the end of the trial
125 (Table 3).

126 Of these 141 individuals, 22 carried pathogenic variants in genes associated with hereditary breast and
127 ovarian cancer (*BRCAl/2*), 19 in genes associated with Lynch syndrome or familial adenomatous
128 polyposis (*MLH1*, *MSH2*, *PMS2*, *MSH6*, *APC*), 12 in genes associated with familial hypercholesterolemia
129 (*LDLR*, *APOB*, *PCSK9*), and 88 in genes associated with other inherited cardiac disorders or genetic
130 arrhythmias (*KCNQ1*, *KCNH2*, *SCN5A*, *MYBPC3*, *LMNA*, *MYH11*, *MYH7*, *MYL3*, *TNNT2*, *GLA*, *PKP2*,
131 *DSC2*, *DSG2*, *DSP*, *TMEM43*, *RYR2*, *FBN1*).

132 **Table 3. Identification of Pathogenic Variant Carriers in ASPREE Free of Associated Autosomal**
 133 **Dominant Genetic Disease to Mean Age 79.5 Years ('Resilience candidates').**

135 We identified pathogenic variants in 55 autosomal dominant disease genes in 13,131 healthy elderly
 136 individuals enrolled in the ASPREE trial. We grouped related genes for autosomal dominant conditions
 137 and defined associated disease events in participant medical history (prior to study enrolment) and
 138 prospective disease diagnoses occurring during the ASPREE trial to median age 79.5 years.
 139

Mean age = 79.5 years		Pathogenic Variant Carriers in ASPREE			
		Total	With Associated Disease ^a	Without Associated Disease ^a <i>'Resilient'</i>	% Free of Associated Disease
Hereditary breast and ovarian cancer syndrome (BRCA1, BRCA2), N=33 carriers					
<i>Cancers</i>	Breast (F)	15	6	9	60%
	Ovarian (F)	15	0	15	100%
	Prostate (M)	18	2	16	89%
	Melanoma	33	3	30	91%
	Pancreatic	33	0	33	100%
	Total ^b	33	11	22	67%
Lynch syndrome (MLH1, MSH2, PMS2, MSH6) & Familial adenomatous polyposis (APC), N=21 carriers					
<i>Cancers</i>	Colorectal	21	1	20	95%
	Cervical/uterine (F)	12	0	12	100%
	Stomach	21	0	21	100%
	Gallbladder/bile duct	21	0	21	100%
	Ovarian (F)	12	1	11	92%
	Total ^b	21	2	19	90%
Familial hypercholesterolemia (LDLR, APOB, PCSK9), N=13 carriers					
<i>CVD</i>	Myocardial infarction	13	1	12	92%
	Large artery atherosclerosis	13	0	13	100%
<i>Deaths</i>	Coronary heart disease	13	0	13	100%
	Total ^b	13	1	12	92%
Inherited cardiac disorders combined: Romano-Ward long QT syndrome (1,2,3), Brugada syndrome (KCNQ1, KCNH2, SCN5A), Hypertrophic, dilated cardiomyopathy (MYBPC3, LMNA, MYH11, MYH7, MYL3, TNNT2, GLA), Arrhythmogenic right-ventricular cardiomyopathy (PKP2, DSC2, DSG2, DSP, TMEM43), Catecholaminergic polymorphic ventricular tachycardia (RYR2), Marfan, Loeys-Dietz syndromes, and familial thoracic aortic aneurysms and dissections (FBN1), N=91 carriers					
<i>CVD</i>	Hospitalisation for heart failure	91	1	90	99%
<i>Deaths</i>	Rapid/sudden cardiac	91	2	89	98%
	Total ^b	91	3	88	97%
	Grand Total ^b	158	17	141	89%

140 ^aTo mean age 79.5 years, includes both associated disease events reported in personal medical history prior to study
 141 enrolment, and prospective events occurring during the ASPREE trial.

142 ^bParticipants with >1 associated disease event were only counted once
 143 (F) = Female, (M) = Male
 144
 145
 146

147 DISCUSSION

148 In the present study, we sequenced the DNA of 13,131 healthy elderly individuals and identified 141
149 apparent resilient carriers of pathogenic variants in genes which typically predispose to autosomal
150 dominant conditions. Despite having a supposedly high genetic risk of disease, these individuals remained
151 apparently unaffected until a mean age of 79.5 years. They were identified among a population of healthy
152 elderly individuals meeting the strict eligibility criteria of the ASPREE trial (22). These elderly surviving
153 pathogenic variant carriers are likely to be enriched for protective genetic factors.

154 There are important differences between resilience to childhood-onset and adult-onset genetic disorders.
155 Many childhood-onset genetic disorders are autosomal recessive and fully penetrant, meaning when a copy
156 of a pathogenic genetic variant is inherited from both parents, it almost always results in severe disease
157 from an early age. Adult-onset conditions, by contrast, tend to be autosomal dominant, with only a single
158 pathogenic variant required to confer risk or predisposition to disease. These conditions tend to occur later
159 in life (25). Such conditions include hereditary breast and ovarian cancer (7), Lynch syndrome (9) and
160 familial hypercholesterolemia (27). Most autosomal dominant conditions are not fully penetrant, meaning
161 not all carriers of pathogenic variants develop the associated disease. Thus, a sub-set of pathogenic variant
162 carriers for autosomal dominant conditions will remain unaffected, despite being at high genetic risk (28).
163 These individuals (the lifelong unaffected) are less likely to be recruited in traditional genetic studies that
164 ascertain participants on the basis of family or personal history of disease symptoms.

165 The pathogenic variants identified in this study might prompt medical interventions if detected at younger
166 ages. For example, the risk management of pathogenic *BRCA1/2* variants might include risk-reducing
167 bilateral mastectomy and bilateral salpingo-oophorectomy in younger women. Variants in other cancer-
168 associated genes can also lead to risk-reducing surgeries or long-term high-risk cancer surveillance (29-
169 31). Detection of pathogenic variants in inherited cardiac disorder genes might lead to implantation of
170 automatic defibrillators (32). These interventions have substantial implications for both individuals and
171 the healthcare system.

172 By comparison with the largest available population-based sequencing dataset (the UK Biobank) (26), we
173 found the overall prevalence of pathogenic autosomal dominant variants to be higher (20 per 1000) than
174 in ASPREE (13 per 1000). Differences in sequencing technology, variant curation or ethnic diversity may
175 account for some variation in frequencies of pathogenic variants between the studies. However, the
176 difference is also compatible with a survival disadvantage during the middle years of life.

177 In particular, the frequency of female *BRCA1/2* variant carriers in ASPREE was half that reported in the
178 UK Biobank, reflecting a high penetrance of the *BRCA1/2* genes. Similarly, lower frequencies of variant
179 carriers for the more penetrant Lynch syndrome genes (*MSH6*, *MLH1*, *MSH2*) was also observed, but not
180 for the less penetrant (*PMS2*). For other genes, the carrier rate per 1000 was equivalent between ASPREE

181 and the UK Biobank (e.g. *BRC1A1*, *PMS2*, *MYBPC3*, *PKP2*, *SDHB*, *SDHC*, *SDHD*) and for occasional
182 genes the carrier rate in ASPREE was higher (e.g. *KCNQ1*, *KCNH2*, *SCN5A*).

183 Our previous analysis of 589,306 genomes identified 13 rare exceptional ‘resilience candidates’, who
184 despite having mutations that cause severe childhood-onset genetic disease, had no reported clinical
185 symptoms to adulthood (13). Unfortunately, these individuals were identified through data aggregation
186 from several different studies, meaning recontact or follow-up were not possible. Here, individuals have
187 been identified who are resilient to adult-onset genetic disease by direct genomic screening of a healthy
188 elderly cohort, accompanied by documented clinical outcome assessment, and with consent for re-contact
189 (14).

190 The 141 resilience candidates identified now represent a unique sub-cohort for identification of protective
191 genetic factors. Follow-up studies include deeper genomic characterization by whole genome sequencing
192 and genome-wide genotyping, to determine the contribution of rare and common genetic factors towards
193 risk modification (28). Contributions from environmental and lifestyle factors will also be examined
194 through access to detailed longitudinal data collected by the ASPREE Longitudinal Study of Older
195 Persons (33). Comparisons of ASPREE resilience candidates with other sample cohorts (e.g. case
196 collections of those affected by early-onset disease for the same genes/conditions) are also being planned.

197 A strength of the current study is the detailed phenotyping with ascertainment and adjudication of outcome
198 events during the 4.5 years of follow-up. The age of the cohort (all participants being above the average
199 age of onset for most dominant conditions) has also facilitated the identification of those most likely to
200 be resilient to disease development. Other strengths include the depth of sequencing coverage and
201 stringency of variant curation applied, ensuring all pathogenic variant calls were of high confidence.

202 Our findings provide a scalable approach for more expansive genomic screening of the healthy elderly,
203 to identify those resilient to adult-onset genetic disease. We identified resilience candidates in the healthy
204 elderly at a rate of 1.07% (141 in 13,131 ASPREE participants). Projecting this to a larger sample
205 population of 1 million healthy elderly individuals would estimate identification of over 10,000 resilience
206 candidates. Such a population would provide the foundation for a statistical genetic study, with sufficient
207 sample size to potentially identify protective genetic variants of genome-wide statistical significance (15).
208 Such an approach is currently under consideration, involving both data mining of existing large
209 population-based datasets for the healthy elderly, such as the UK Biobank (26), and direct screening of
210 more community-based biobank cohorts of the healthy elderly, including the Statins in Reducing Events
211 in the Elderly (STAREE), which is currently recruiting (14).

212 Our study also raises a clinically relevant question of whether there is an indicative age at which
213 pathogenic variant carriers for dominant conditions outlive their genetic risk; that is, whether there is an
214 age at which genetic risk and population risk for carriers of autosomal dominant pathogenic variants

215 converge and become equal. Previous studies suggest the majority of clinical risk attributed to dominant
216 pathogenic variants diminishes by age 70, especially for cancer (7, 9).

217 Limitations of our study include the ASPREE trial not originally being designed to analyse certain
218 dominant genetic disease phenotypes. For example, electrocardiograms were not collected on all
219 participants to detect cardiac abnormalities in pathogenic variant carriers for arrhythmia-related genes.
220 We instead relied on hard study endpoints such as sudden cardiac death to define disease association in
221 those genes. Technical limitations include a sequencing assay that was not capable of detecting pathogenic
222 structural variants, including those in *MSH2* and other mismatch repair genes. This, in addition to the
223 strict variant curation and filtering criteria, may have resulted in an under-estimation of pathogenic variant
224 carriers identified. Some pathogenic variant carriers detected in ASPREE may have undergone risk-
225 reducing surgery prior to study enrolment (including hysterectomy, for example, which removes ovarian
226 cancer risk if ovaries are removed), and not reported this to ASPREE in the cancer screening history
227 questionnaire (22). If this occurred in the absence of any cancer diagnosis, it could result in mis-attribution
228 of resilience. Although unlikely, we cannot currently rule out this possibility without re-contacting the 41
229 resilient candidates for cancer-associated genes.

230 In summary, the study demonstrates that a proportion of healthy elderly carry pathogenic variants in
231 medically actionable genes yet remain mostly free of associated disease. This provides a platform for the
232 discovery of protective genetic factors in this uniquely resilient population, and a scalable method for
233 identification of more resilient individuals in the future.

234 ACKNOWLEDGEMENTS

235 The ASPREE Healthy Ageing Biobank is supported by a Flagship cluster grant (including the
236 Commonwealth Scientific and Industrial Research Organisation, Monash University, Menzies Research
237 Institute, Australian National University, University of Melbourne); and grants (U01AG029824) from the
238 National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants
239 (334047 and 1127060) from the National Health and Medical Research Council of Australia, and by
240 Monash University and the Victorian Cancer Agency. We thank the trial staff in Australia and the United
241 States, the participants who volunteered for this trial, and the general practitioners and staff of the medical
242 clinics who cared for the participants.

243

244 COMPETING INTERESTS

245 The authors declare no competing financial interests.

246

247 ETHICAL APPROVAL

248 This work was approved by the Alfred Hospital Human Research Ethics Committee (Project 390/15) in
249 accordance with the National Statement on Ethical Conduct in Human Research (2007).

250

251 AUTHOR CONTRIBUTIONS

252 PL and RS conceived the study; I.W, E.S and J.J.M directed the research; J.J.M, R.L.W, A.M.M, A.M.T,
253 M.R.N and C.M.R directed the ASPREE trial; J.R, M.R, M.S, Y.C.W, R.C, B.A.T, D.D.B, P.A.J
254 contributed to genetic analysis and variant curation; P.G and F.A.M contributed to adjudication of cancer
255 outcomes; A.M.T was Chair of the cardiovascular outcomes adjudication committee; R.L.W, J.P, E.J.P,
256 S.G.O, W.P.A, T.J.L, R.L.W, and J.J.M contributed to collection of biospecimens; R.S, R.C, D.S, T.A,
257 M.S, Y.C.W and E.S contributed to panel design, DNA sequencing and variant calling; D.S, M.R and J.R
258 contributed to the preparation of genetic data; J.E.L, S.G.O and R.L.W contributed to the preparation of
259 phenotype data; D.D.B, F.A.M, P.A.J and I.W contributed to clinical interpretation of genetic variants;
260 M.R and R.W contributed to statistical analyses; P.L wrote the manuscript, with editing from J.T, R.S,
261 I.W and J.J.M. All authors reviewed the manuscript.

262 REFERENCES

- 263 1. Lacaze P, Pinese M, Kaplan W, Stone A, Brion MJ, Woods RL, et al. The Medical Genome
264 Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and
265 cohort design. *Eur J Hum Genet.* 2019;27(2):308-16.
- 266 2. Erikson GA, Bodian DL, Rueda M, Molparia B, Scott ER, Scott-Van Zeeland AA, et al. Whole-
267 Genome Sequencing of a Healthy Aging Cohort. *Cell.* 2016;165(4):1002-11.
- 268 3. Deelen J, Evans DS, Arking DE, Tesi N, Nygaard M, Liu X, et al. A meta-analysis of genome-wide
269 association studies identifies multiple longevity genes. *Nat Commun.* 2019;10(1):3669.
- 270 4. Deelen J, van den Akker EB, Trompet S, van Heemst D, Mooijaart SP, Slagboom PE, et al.
271 Employing biomarkers of healthy ageing for leveraging genetic studies into human longevity. *Exp*
272 *Gerontol.* 2016;82:166-74.
- 273 5. Beekman M, Blanche H, Perola M, Hervonen A, Bezrukov V, Sikora E, et al. Genome-wide linkage
274 analysis for human longevity: Genetics of Healthy Aging Study. *Aging Cell.* 2013;12(2):184-93.
- 275 6. Tindale LC, Leach S, Spinelli JJ, Brooks-Wilson AR. Lipid and Alzheimer's disease genes associated
276 with healthy aging and longevity in healthy oldest-old. *Oncotarget.* 2017;8(13):20612-21.
- 277 7. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of
278 Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA.*
279 2017;317(23):2402-16.
- 280 8. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline
281 BRCA1 mutations increase prostate cancer risk. *Br J Cancer.* 2012;106(10):1697-701.
- 282 9. Moller P, Seppala TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and
283 survival in *path_MMR* carriers by gene and gender up to 75 years of age: a report from the Prospective
284 Lynch Syndrome Database. *Gut.* 2018;67(7):1306-16.
- 285 10. Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, et al. Cancer
286 Risks for PMS2-Associated Lynch Syndrome. *J Clin Oncol.* 2018;36(29):2961-8.
- 287 11. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical
288 Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe
289 Hypercholesterolemia. *J Am Coll Cardiol.* 2016;67(22):2578-89.
- 290 12. Friend SH, Schadt EE. Translational genomics. Clues from the resilient. *Science.*
291 2014;344(6187):970-2.
- 292 13. Chen R, Shi L, Hakenberg J, Naughton B, Sklar P, Zhang J, et al. Analysis of 589,306 genomes
293 identifies individuals resilient to severe Mendelian childhood diseases. *Nat Biotechnol.* 2016;34(5):531-
294 8.
- 295 14. Lacaze P, Woods R, Zoungas S, McNeil J, Group AI, Biobank AHA, et al. The genomic potential of
296 the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies.
297 *Internal medicine journal.* 2017;47(4):461-3.
- 298 15. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS
299 Discovery: Biology, Function, and Translation. *American journal of human genetics.* 2017;101(1):5-22.
- 300 16. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of Aspirin on
301 Cardiovascular Events and Bleeding in the Healthy Elderly. *N Engl J Med.* 2018;379(16):1509-18.
- 302 17. McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of Aspirin on
303 Disability-free Survival in the Healthy Elderly. *N Engl J Med.* 2018;379(16):1499-508.
- 304 18. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of Aspirin on All-
305 Cause Mortality in the Healthy Elderly. *N Engl J Med.* 2018;379(16):1519-28.
- 306 19. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting
307 of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy
308 statement of the American College of Medical Genetics and Genomics. *Genetics in medicine : official*
309 *journal of the American College of Medical Genetics.* 2017;19(2):249-55.
- 310 20. Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, et al. Feasibility of conducting a
311 primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in

- 312 Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. *The Medical*
313 *journal of Australia*. 2008;189(2):105-9.
- 314 21. Lockery JE, Collyer TA, Abhayaratna WP, Fitzgerald SM, McNeil JJ, Nelson MR, et al. Recruiting
315 general practice patients for large clinical trials: lessons from the Aspirin in Reducing Events in the
316 Elderly (ASPREE) study. *The Medical journal of Australia*. 2019;210(4):168-73.
- 317 22. McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, et al. Baseline Characteristics
318 of Participants in the ASPREE (ASPIrin in Reducing Events in the Elderly) Study. *The journals of*
319 *gerontology Series A, Biological sciences and medical sciences*. 2017;72(11):1586-93.
- 320 23. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive
321 of relationships among sequence variation and human phenotype. *Nucleic acids research*.
322 2014;42(Database issue):D980-5.
- 323 24. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-
324 coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285-91.
- 325 25. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the
326 interpretation of sequence variants: a joint consensus recommendation of the American College of
327 Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in medicine* :
328 *official journal of the American College of Medical Genetics*. 2015;17(5):405-24.
- 329 26. Van Hout CV TI, Backman JD, Hoffman JX, Ye B, Pandey AK, Gonzaga-Jauregui C, Khalid S, Liu D,
330 Banerjee N, Li AH, O'Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L,
331 Lopez A, Penn J, Habegger L, Blumenfeld AL, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK,
332 Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH, Geisinger-Regeneron DiscovEHR
333 Collaboration, Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S,
334 Cantor M, Nelson MR*, Whittaker J*, Reid JG*, Marchini J*, Overton JD*, Scott AR*, Abecasis G*,
335 Yerges-Armstrong L*, Baras A* on behalf of the Regeneron Genetics Center. Whole exome sequencing
336 and characterization of coding variation in 49,960 individuals in the UK Biobank. *bioRxiv preprint first*
337 *posted online Mar 9, 2019*. 2019.
- 338 27. Jackson CL, Keeton JZ, Eason SJ, Ahmad ZA, Ayers CR, Gore MO, et al. Identifying Familial
339 Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer
340 Donors. *JAMA Cardiol*. 2019.
- 341 28. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is
342 not predictive of phenotype: Towards an understanding of the molecular basis of reduced penetrance in
343 human inherited disease. *Human Genetics*. 2013;132(10):1077-130.
- 344 29. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-
345 reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA*.
346 2010;304(9):967-75.
- 347 30. Evans DG, Kesavan N, Lim Y, Gadde S, Hurley E, Massat NJ, et al. MRI breast screening in high-
348 risk women: cancer detection and survival analysis. *Breast Cancer Res Treat*. 2014;145(3):663-72.
- 349 31. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery
350 to reduce the risk of gynecologic cancers in the Lynch syndrome. *The New England journal of medicine*.
351 2006;354(3):261-9.
- 352 32. Hosseini SM, Kim R, Udupa S, Costain G, Jobling R, Liston E, et al. Reappraisal of Reported Genes
353 for Sudden Arrhythmic Death. *Circulation*. 2018;138(12):1195-205.
- 354 33. McNeil JJ, Woods RL, Ward SA, Britt CJ, Lockery JE, Beilin LJ, et al. Cohort Profile: The ASPREE
355 Longitudinal Study of Older Persons (ALSOP). *International journal of epidemiology*. 2019.

356